Insulin independence for LCT
Tuesday, 07 April, 2009
New Zealand’s Living Cell Technologies has reported that a patient with type 1 diabetes is currently insulin independent following treatments in an early stage trial.
LCT is running the safety and dosing trial in Moscow. Seven patients have received Diabecell implants at a low or medium dose.
Diabecell is a microencapsulated product containing insulin-producing porcine islet cells. In the female patient, live porcine cells in their capsules have been found in the abdomen and porcine insulin was detected in her blood.
The 37-year-old had been on daily insulin injections for 15 years. She is now maintaining good blood glucose control without injections, LCT said.
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
